UCLH doses first patient in the world in Covid-19 antibody trial
Excerpt from the Press Release:
UCLH has opened a new vaccine research centre with two clinical trials testing a long-acting antibody combination treatment to protect against Covid-19.
Researchers in the STORM CHASER study led by UCLH virologist Dr Catherine Houlihan have recruited the first participant in the world to the study.
They believe the antibody or LAAB, known as AZD7442 and developed by AstraZeneca, may offer immediate and long-term protection to people who have been recently exposed to the SARS-CoV-2 virus, to prevent them developing Covid-19.
Dr Houlihan, also of UCL Infection & Immunity, said: “We know that this antibody combination can neutralise the virus, so we hope to find that giving this treatment via injection can lead to immediate protection against the development of Covid-19 in people who have been exposed – when it would be too late to offer a vaccine.”
Click the button below to continue reading the Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?